滚动资讯
Samsung BiologicsSamsung Biologics Labor Talks Break Down, Gap Remains - thelec.netSiemens Healthineers西门子医疗总睾酮检测获CDC HoSt-TT认证，扩大患者获取金标准等效结果 - Medical NewsSamsung BiologicsSamsung Biologics union continues first general strike, demands higher wages and performance-based pay - Korea JoongAng DailyFierceBiotech瑞士私营生物科技公司融资创纪录，公共融资放缓Samsung BiologicsSamsung Biologics' strike enters 5th day - Yonhap News AgencyEndpoints NewsVertex因‘耐受性’问题终止mRNA囊性纤维化项目Bio-RadBio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab ManagerFierceBiotechVertex放弃与Moderna合作的吸入式囊性纤维化候选药物，因耐受性问题未解ModernaVertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues - Fierce BiotechAmgenBiotech Outpaced Health Care As Sanofi And Amgen Slipped - FinimizeLabCorpLabcorp raises full-year forecasts on steady diagnostics demand - MSNVertexVertex Pharma posts mixed Q1 results; Shares edge lower - Investing.com
FierceBiotech 2026年3月20日

基因泰克抗体未能增强罕见疾病患者肌肉，引发对肥胖试验的质疑。

基因泰克抗体未能增强罕见疾病患者肌肉，引发对肥胖试验的质疑。

原文
暂时没有全文，请查看原始来源。